Alfredo Sebastián Golemba, Specialist Physician in Oncology at the Caribbean Cancer Center, CECAC Ltd., shared a post on LinkedIn:
“Proud of our latest publication “Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center“.
We know that patients with early-stage HR+/HER2- BC still face risks of early (≤5 years) and late (>5 years) recurrence despite treatment, regardless of nodal involvement.
We performed a retrospective study in 334 patients with HR+/HER2- eBC (stages I-III) with the objective to determine the clinical characteristics and distribution of patients eligible for CDK4/6i in the adjuvant setting.
Results
- 𝐀𝐛𝐞𝐦𝐚𝐜𝐢𝐜𝐥𝐢𝐛-𝐞𝐥𝐢𝐠𝐢𝐛𝐥𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬: 𝟑𝟔.𝟐% (𝐧=𝟏𝟐𝟏), 𝟓𝟒.𝟓% 𝐡𝐚𝐝 ≥𝟒 𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐧𝐨𝐝𝐞𝐬.
- 𝐑𝐢𝐛𝐨𝐜𝐢𝐜𝐥𝐢𝐛-𝐞𝐥𝐢𝐠𝐢𝐛𝐥𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬: 𝟓𝟗% (𝐧=𝟏𝟗𝟕), 𝟓𝟑.𝟖% 𝐰𝐢𝐭𝐡 𝐬𝐭𝐚𝐠𝐞 𝐈𝐈𝐈 𝐝𝐢𝐬𝐞𝐚𝐬𝐞.
The findings reveal that a significant percentage of these patients would be candidates for abemaciclib or ribociclib, with important clinical, economic, and healthcare access implications for the Colombian health system.
𝐄𝐥𝐢𝐠𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐝𝐨𝐞𝐬 𝐧𝐨𝐭 𝐞𝐪𝐮𝐚𝐥 𝐚𝐜𝐜𝐞𝐬𝐬!
Multiple questions arise in this scenario.
Beyond the economic and quality-of-life implications of this strategy, how do we identify those patients who will not experience a relapse of the disease despite having high risk factors for recurrence and who are treated with the treatment considered standard for years?
How do we identify those patients who will experience early systemic relapses despite receiving standard treatment plus CDK4/6i? We know that approximately 10% of patients will have this relapse pattern, generally with a TN phenotype and genotype. ADCs?
Our results highlight the need for more effective breast cancer early detection strategies in Colombia.
Special thanks to Pablo Mandó and Centro Cancerológico del Caribe, CECAC Ltda.”
Title: Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center
Authors: Alfredo Sebastián Golemba, Pablo Mando, Adriana Lucia Jimenez Bolaño, Shirly Patricia Rodríguez Torres, Rusvelt Vargas Moranth, Astor Alfonso Aguirre Santamaria.
Read the full article.
More posts featuring Alfredo Sebastián Golemba